KRAS and non-small cell lung carcinoma: The observed adverse prognostic significance of TP53 mutations in NSCLC is strengthened by a further stratification: patients with only TP53 alterations had a poorer prognosis compared to those with KRAS-only mutations or those with KRAS and TP53 WT status.